Dr. Adams to further advance promising pipeline, including breakthrough therapy, NiCord, in phase 3 development as a universal bone marrow transplant solution. Source: BioSpace

PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018. Source: BioSpace

Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. Source: BioSpace

Celgene loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics. Source: BioSpace

A look at six bay area-based VCs who are creating a lot of value in biotech. Source: BioSpace

CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis. Source: BioSpace

A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace

Genentech scored two approvals from the FDA this week. Source: BioSpace

The approval was based on results from a trial that demonstrated a significant reduction in the risk of a disease-free survival (DFS) event for patients at high risk of RCC…

Bloomberg noted that Takeda's CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus. Source: BioSpace